Roivant brings rare disease program closer as Immunovant CEO retiresnews2025-04-21T11:00:57+00:00April 21st, 2025|Endpoints News|
Roche discontinues low dose in Huntington’s trialnews2025-04-17T15:30:48+00:00April 17th, 2025|Endpoints News|
Netherlands pours $1.5B into biotech in pursuit of global leadership ambitionsnews2025-04-17T11:21:28+00:00April 17th, 2025|Endpoints News|
Eli Lilly reports Phase 3 trial win for oral GLP-1 in diabetesnews2025-04-17T10:45:43+00:00April 17th, 2025|Endpoints News|
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50snews2025-04-16T20:04:53+00:00April 16th, 2025|Endpoints News|
Glycomine raises $115M to target rare glycosylation disordernews2025-04-16T11:00:23+00:00April 16th, 2025|Endpoints News|
Mural Oncology ends clinical development, lays off most workersnews2025-04-15T13:39:18+00:00April 15th, 2025|Endpoints News|
Sanofi’s Kymab-originated inflammatory drug flunks mid-stage asthma trialnews2025-04-15T13:19:24+00:00April 15th, 2025|Endpoints News|
FDA clears clinical trial of gene-edited pig liver used outside of bodynews2025-04-15T12:00:34+00:00April 15th, 2025|Endpoints News|
Merck taps Cyprumed’s drug delivery platform for oral peptidesnews2025-04-15T07:00:03+00:00April 15th, 2025|Endpoints News|
